Table 2.
Mycophenolate Related Anemia and Leukopenia Toxicity
| Subjects with toxicity | Subjects without toxicity | |
|---|---|---|
| Anemia (n=918)1 | 87 | 831 |
|
| ||
| Median days to anemia or censoring (95% CI) | 45 (34–55) | 183 (183–183) |
| Age (mean±SD) | 51.6±14.5 | 48.8±13.9 |
| Weight (kg) at transplant (mean±SD) | 79.2±22.8 | 81.8±20.0 |
| Male gender | 56.3% | 62.8% |
| Prior kidney transplant | 17% | 14% |
| Living donor | 51% | 61% |
| Thymoglobulin induction | 66% | 52% |
| Concomitant medications | ||
| Cyclosporine | 57%, (26%)2 | 35%, (24%)2 |
| Tacrolimus | 39%, (0%)2 | 63%, (5%)2 |
| Corticosteroids | 44%3 | 50%3 |
| Antiviral prophylaxis | 91%4 | 95%4 |
| Posttransplant dialysis | 22% | 7% |
| CMV serostatus pretransplant (R−/D−, R+, R−/D+)3 | 18%, 55%, 21% | 21%, 59%, 16% |
|
| ||
| Leukopenia (n=978)1 | 224 | 754 |
|
| ||
| Median days to leukopenia or censoring (95% CI) | 81.5 (76–88) | 183 (183–183) |
| Age (mean±SD) | 47.7±15 | 49.6±13.7 |
| Weight at transplant (mean±SD) | 78.3±20.2 | 82.2±20.0 |
| Male gender | 60% | 63% |
| Prior kidney transplant | 10% | 15% |
| Living donor | 53% | 60% |
| Thymoglobulin induction | 60% | 49% |
| Concomitant medications | ||
| Cyclosporine | 37%, (22%)2 | 35%, (25%)2 |
| Tacrolimus | 61%, (7%)2 | 63%, (4%)2 |
| Corticosteroids | 65%3 | 41%3 |
| Antiviral prophylaxis | 98%4 | 92%4 |
| Posttransplant dialysis | 8.5% | 8% |
| CMV serostatus (R−/D−, R+, R−/D+)5 | 18%, 53%, 23% | 22%, 61%, 14% |
1
Number of subjects analyzed.
2
% of patients receiving concomitant calcineurin inhibitor anytime within the 14 days posttransplant (% switched off the calcineurin inhibitor at anytime in the first 6 months posttransplant),
3
%of patients who never received corticosteroids or stopped taking corticosteroids within 14 days posttransplant,
4
% of patients who received antiviral prophylaxis at any time while at risk for toxicity,
5
Pretransplant CMV serostatus missing in 44 subjects.